Codrituzumab clinical trials
Also written GC33.
How each study uses codrituzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the codrituzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Chugai Pharmaceutical (2) · Hoffmann-La Roche (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test codrituzumab.
- Jun 2027A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After TreatmentPhase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses codrituzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After TreatmentRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT04928677Written as Codrituzumab
- A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular CarcinomaCompletedPhase 2Hoffmann-La RocheNCT01507168Written as GC33
- Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)CompletedPhase 1Chugai PharmaceuticalNCT00976170Written as GC33(RO5137382)
- A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)CompletedPhase 1Chugai PharmaceuticalNCT00746317Written as GC33
Codes
What other systems call codrituzumab · ClinicalTrials.gg INT000696
- MeSH (NLM) C000619938codrituzumabOne source NLM
- UNII (FDA) U9I0PLD4HTCODRITUZUMABConfirmed FDA, NLM
- NCI Thesaurus C80043CodrituzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619938 | codrituzumab | One source NLM |
| UNII (FDA) | U9I0PLD4HT | CODRITUZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C80043 | Codrituzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.